Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C9 VHH CAR-T
- Development stage
- Preclinical
- Lead developer
- Shanghai HRAIN Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
11C9 VHH CAR-T is a preclinical chimeric antigen receptor T-cell (CAR-T) therapy targeting CD70, a protein highly expressed in various hematopoietic and solid tumors, including renal cell carcinoma (RCC). Developed by HRAIN Biotechnology, the therapy utilizes a VHH (variable domain of heavy chain-only antibody, or nanobody) derived from an immunized alpaca as its antigen-binding domain. The 11C9 VHH was selected for its superior expansion and cytokine production (specifically IL-2) compared to other VHH clones and traditional scFv-based CARs. In preclinical studies, 11C9 CAR-T cells demonstrated robust anti-tumor activity, expanding over 250-fold after infusion and maintaining tumor-free status in mice even after tumor re-challenge.
- Other names
- anti-CD70 VHH CAR-Tanti-CD-70 VHH CAR-Tanti-CD 70 VHH CAR-T
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on 11C9 VHH CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11C9 VHH CAR-T.